His group was the first to publish findings of dramatic molecular remissions in patients with chemorefractory acute
lymphoblastic leukemia following treatment with autologous CD19 - targeted T cells.
Not exact matches
Juno Therapeutics will resume its Phase II ROCKET clinical trial of its acute
lymphoblastic leukemia candidate JCAR015
following the FDA's lifting of a partial clinical hold imposed last week
following the deaths of three patients.
Juno Therapeutics is seeking to change the protocol for the Phase II ROCKET clinical trial of its acute
lymphoblastic leukemia candidate JCAR015, which the FDA has placed on clinical hold
following the deaths of three patients, two of them last week.